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Background: Several reports have revealed that cancer stem cells (CSCs) exist in many types of solid tumors. Some
studies have demonstrated that side population (SP) cells isolated from diverse cancer lines harbor cancer stem-like
properties, but there are few reports examining the characteristic of SP cells in human cervical cancer. The aim of
this study is 1) to find out a feasible way to detect the tumor stem-like cells in cervical cancer, and 2) to analyze the
properties of the SP cells being sorted.
Methods: Isolated SP and non-SP cells from human cervical cancer cell line Hela by Hoechst 33342 dying method
and flow cytometry analysis. Observing morphology of SP and non-SP cells. The expression of various biomarkers
putatively related to cancer stem cells were investigated by immucytochemistry of SP and non-SP cells. We also
analyzed cell cycle and cell apoptosis for sorted cells. The oncogenicity of the SP and non-SP cells were analyzed by
tumor formation in nonobesediabeti- c/severe combined immune- deficient (NOD/SCID) mice. The drug-resistant and
radiation-resistant index between SP, non-SP and Hela cells was estimated by MTS assay.
Results: The fraction of SP cells in Hela was approximately 1.07 ± 0.32%. SP cells were smaller and rounder in shape
than non-SP cells, and mostly showed colony-like growth. Immunocytochemistry showed that stem cell makers (Oct3/4,
CD133, BCRP) were highly expressed in SP cells. Moreover, the number of apoptotic cells among non-SP cells (17.6 ±
3.7%) was significantly higher compared with that among SP cells (4.4 ± 1.2%). The HE staining of in vivo grown tumors
result from SP cells showed more poor differentiation, though no significant differences were shown between SP and
non-SP cells in NOD/SCID mice tumorigenicity. Furthermore, SP cells demonstrated a higher degree of drug resistance
against trichostatin A (TSA) compared with that of non-SP and Hela cells. SP cells were also found to be more resistant
against radiotherapy.
Conclusions: SP cells possess some characteristics of CSCs, namely high proliferation ability, chemoresistance and
radioresistance, which may be helpful to elucidate novel targets for effective clinical treatments of cervical cancer in the
future.
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RadioresistanceBackground
Cervical cancer is a common gynecological malignancy.
Persistent human papilloma virus infection has been rec-
ognized as the primary pathogenic factor for the devel-
opment of cervical cancer, however its mechanism
remains unclear. Recent studies have shown that tumor
tissues contain a very small number of stem-like cells* Correspondence: weilh19@china.com
†Equal contributors
1Department of Gynecology and Obstetrics, Peking University People's
Hospital, 11 Xizhimen South Street, Xicheng District, Beijing 100044, China
Full list of author information is available at the end of the article
© 2014 Qi et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthat are responsible for self-renewal, differentiation,
tumor growth, metastasis and recurrence [1,2]. Hence,
an increasing number of studies have been conducted
on cancer stem cells (CSCs) in an attempt to identify the
mechanisms of the genesis, development and drug re-
sistance of tumors. The principal problem of the relevant
research is the isolation and identification of CSCs. Be-
cause of lack of markers, CSCs have been mainly isolated
by approach of isolating adult stem cells. These methods
include cell sorting based on the expression of surface
biomarkers, suspension sphere culture, and functional cellThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(side population (SP) cell sorting).
In 1996, Goodell et al. [3] discovered SP cells when
examining mouse bone marrow hematopoietic stem cells
using the fluorescent dye Hoechst 33342. After more than
a decade of research, SP cells are considered to be a com-
mon phenotype of stem cells. To date, SP cells have been
isolated from many tumor tissues and cell lines such as
blood [4], breast [5], glioma [5], cervix [5], liver [6], ovar-
ian [7], lung [8], and pancreas [9]. Further experiments
have confirmed that SP cells possess CSC-like features in-
cluding self-renewal, asymmetric division into SP and
non-SP cells, and apparent drug resistance. Many reports
indicate that SP cells are an ideal model for stem cell
research [10]. The characteristic of SP cells to rapidly
extrude Hoechst 33342 is based on the expression of
ABCG2/BCRP1, a breast cancer resistance protein (BCRP)
of the ATP-binding cassette (ABC) transporter family.
ABCG2/BCRP1 is a transmembrane protein that plays an
important role in the multidrug resistance (MDR) of
tumor cells [11]. The expression of ABCG2/BCRP1 shows
a strong positive correlation with the phenotype of SP
cells in a series of studies, which is the molecular basis of
the phenotypic characteristics of SP cells [12]. High ex-
pression of ABCG2/BCRP1 in SP cells is contributed to
drug resistance and tumor recurrence [10].
In 2004, Kondo et al. [5] reported that the SP cells iso-
lated from the cervical cancer cell line HeLa account for
approximately 1.2% of the total number of HeLa cells.
However, few studies have reported on the phenotypic
identification of SP cells among HeLa cells. The present
study attempts to find an effective method for the isola-
tion of cervical CSCs. We sorted and cultured SP cells
from the cervical cancer cell line HeLa, and then identi-
fied their stem-like characteristics. This study may be
helpful to elucidate novel targets for effective clinical
treatments of cervical cancer.
Results
SP cells among HeLa cells
After excluding dead cells and cellular debris based on
scatter signals and propidium iodide (PI) fluorescence,
the SP and non-SP cells were sorted. In multiple inde-
pendent HeLa cultures, we detected 1.07 ± 0.32% SP
cells as shown in Figure 1A.
After 6 hour plating, observation of the morphology of
SP and non-SP cells revealed that the SP cells were more
adherent than non-SP cells. In addition, the sorted SP
cells were smaller and rounder in shape than non-SP
cells, and mostly showed colony-like growth (Figure 1B).
Expression of various biomarkers related to stem cells
The expression of various biomarkers putatively related to
CSCs was investigated in freshly sorted SP and non-SPfractions of HeLa cells (Figure 2). Considering that the
expression of Oct3/4 mainly occurs in the nucleus,
hematoxylin counterstaining of the nucleus was omitted
in the immunocytochemical analysis. The results showed
that Oct3/4 was mainly expressed in the nucleus, and a
small amount of Oct3/4 was found in the cytoplasm. The
expression level of Oct3/4 in SP cells was substantially
higher than that in non-SP cells. CD133 and BCRP were
mainly expressed in the cytoplasm, and their expression
levels were substantially higher in SP cells compared with
non-SP cells. Notably, BCRP was hardly expressed in non-
SP cells. ALDH-1 was expressed in the cytoplasm of SP
and non-SP cells, and the expression level was almost the
same in SP and non-SP cells. These results indicate that
the phenotype of SP cells is closely related to the expres-
sion of BCRP and shows a certain correlation with stem
cell-related biomarkers, i.e., Oct3/4 and CD133.
Cell cycle and apoptosis analyses
We analyzed the cell cycle of SP and non-SP cells sorted
from HeLa cell line. No significant difference was ob-
served in the cell cycle distribution between SP and
non-SP cells under normal culture conditions. (G1: 43.8 ±
1.8% vs. 43.0 ± 3.4%, P = 0.78; G2: 5.0 ± 1.5% vs. 10.2 ±
3.18%, P = 0.12; S: 51.2 ± 3.3% vs. 46.8 ± 5.6%, P = 0.40;
n = 3) (Figure 3).
We also detected apoptosis by annexin V-PI staining
and flow cytometry at 24 hour after FACS isolation. As
shown in Figure 4, Table 1 the apoptotic rate of non-SP
cells (17.6 ± 3.7%) was significantly higher than that of
SP cells (4.4 ± 1.2%, P = 0.004; n = 3), and the active cells
in SP cells were apparently more than non-SP cells,
which indicated that the anti-apoptosis ability of SP
cells was more efficient (Table 1, Figure 4).
Tumor formation in NOD/SCID mice
We tested the tumorigenic potential of SP and non-SP
cells by tumor incidence, latency (i.e., the time between
tumor cell implantation and when tumors can first be
palpated), and growth rate (i.e., tumor volume). It was
evident that with an decreasing number of injected cells,
the tumor incidence in NOD/SCID mice decreased,
while the latency of tumorigenesis was noticably pro-
longed and the tumor volume gradually decreased. How-
ever, there were no statistically significant differences in
the above-mentioned parameters between SP and non-SP
cells (Table 2, Figure 5A). The t-test showed no statistical
differences in tumor latency and volume between mice in-
oculated with 1 × 105 SP and non-SP cells. Fisher’s exact
test showed no statistical differences in tumor incidence
between mice inoculated with 1 × 104 or 2 × 103 cells. No
statistical analysis was performed on data of the tumor
latency and volume in mice inoculated with 1 × 104 or 2 ×
103 cells because of the insufficient number of samples
Figure 1 Cell sorting results and morphological observation. (A) Sorting of SP cells using Hoechst 33342 (1.07 ± 0.32% to total cells) (left).
When the cells preincubated with verapamil to block the ATP transporter, the SP proportion was reduced to 0 (right). (B) After plating, SP and
non-SP cells were observed every 6 hour, SP cells were more adherent than non-SP cells and showed colony-like growth. The image was
obtained in 24 hour (×100).
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formed to demonstrate that the xenografts in immuno-
deficient mice were generated from the injected human
HeLa cells. We found that the tumor result from SP
cell injection was poorer differentiation (Figure 5B).
SP cells exhibit increased resistance against TSA
(Trichostatin A)
Hela, SP and non-SP cells were treated with varying con-
centrations of TSA. Even at 0.01 μmol/L TSA, the viabil-
ity of SP cells was clearly higher than that of non-SP
cells. As doses of TSA increased, the growth of HeLa and
non-SP cells was obviously suppressed. The suppressive
effect reached the peak when cells were treated with
0.2 μmol/LTSA. The SF (surviving fraction) of sorted SP
cells (86.68 ± 8.78%) was significantly higher than that of
non-SP (49.06 ± 6.26%) and unsorted HeLa cells (43.69 ±4.84%) (P < 0.05). However, TSA had no significant sup-
pressive effect on the growth of SP cells (Figure 6). These
results demonstrate the apparent chemoresistance of
HeLa stem-like cells against anticancer drugs, which may
contribute to tumor recurrence and MDR.
The SF (surviving fraction) of HeLa, SP and non-SP
cells was calculated as follows: SF = experiment OD/
control OD.
Radiation sensitivity
To examine whether the SP cells from the HeLa cell line
possess a radioresistant phenotype, we exposed SP, non-
SP and HeLa cells to X-rays to determine their sensitiv-
ity to radiation. After irradiation, we cultured the cells
for 7 days, and then subjected them to an MTS assay. All
the cell types showed sensitivities to X-ray irradiation, and
their cell proliferation rates decreased with increasing
Figure 2 Expression of putatively CSCs related markers (×400 magnification). Compared to negative control, Oct3/4, CD133 and BCRP
expression in SP cells were higher than non-SP cells. BCRP was scarcely expressed in non-SP cells. ALDH-1 expression showed no visible difference
between SP and non-SP cells (×400).
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SFs of SP, non-SP and HeLa cells were resulted in signifi-
cant differences. As shown in Figure 7, SP cells grew fasterthan non-SP cells when they were exposed to different
does X ray. SP cells showed great radioresistance than the
other cells. On the 7th day after irradiation, the SFs of SP,
Figure 3 Cell cycle of SP and non-SP cells. Cell cycle analysis of sorted SP (A) and non-SP (B) at 24 hours after fluorescence-activated cell
sorting isolation. The results revealed no significant difference between SP and non-SP cells.
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0.73 ± 0.25 vs. 0.51 ± 0.14 vs. 0.58 ± 0.15; 2 Gy, 0.61 ± 0.11
vs. 0.44 ± 0.12 vs. 0.53 ± 0; and 4 Gy, 0.31 ± 0.02 vs. 0.11 ±
0.02 vs. 0.1 ± 0.
Discussion
Since the stem cell theory of cancer was proposed, it
was first confirmed in the field of hematology [13]. Isola-
tion of CSCs from solid tumors is usually performed by
cell sorting based on the expression of putative surface
biomarkers of stem cells. Recent studies of stem cells have
shown that a small population of cells can specifically ex-
trude the DNA dye Hoechst 33342. Such cells show weak
fluorescence in flow cytometry, and have been named as
SP cells. Further studies reported that SP cells are found
in several cancer cell lines, and demonstrate certain stem
cell-like phenotypic characteristics [14-17]. Hence, it is
very likely that SP cells include highly tumorigenic stem-
like cells, which provides a practical method for prelimin-
ary identification and sorting of CSCs. Compared with cell
sorting through surface biomarkers, sorting of SP cells isFigure 4 Cell apoptosis analysis of SP and non-SP cells. Cell apoptosis
lower than that of non-SP cells (B).more convenient, less costly, and universally applicable.
Moreover, the latter can be used to isolate SP cells with
unknown surface biomarkers [18]. Taken together, in the
present study, we used FACS to isolate SP cells from the
human cervical cancer cell line HeLa, and then examined
the biological characteristics of the sorted SP cells.
In 2004, Kondo et al. [5] isolated SP cells from the
HeLa cell line, which accounted for approximately 1.2%
of the total number of HeLa cells. In our study, we ob-
tained sorted SP cells that accounted for 1.07% of the total
number of HeLa cells. The result of SP cells in this study
was mostly consistent with Kondo's. Microscopic observa-
tions showed that the sorted SP cells shared morphological
characteristics with stem-like cells, including smaller size,
rounder shape and higher adherence than non-SP cells, as
well as colony-like growth. This result suggests that SP cells
may possess certain stem cell morphological characteristics.
In addition, we tested the expression of surface markers
of embryonic stem cells and hematopoietic stem cells in
SP and non-SP cells. The expression levels of Oct3/4 and
CD133 in SP cells were significantly higher than those inanalysis showed that the apoptotic rate of SP cells (A) was apparently
Table 1 Apoptosis analysis of SP and non-SP cells
SP cell (%) Non-SP cell (%)
Active cell 95.1 ± 1.4% 84.2 ± 3.6%*
Early apoptosis 1.2 ± 0.6% 2.9 ± 1.6%
Late apoptosis 3.2 ± 0.8% 14.7 ± 5.2%
Necrotic cell 0.5 ± 0.3% 1.5 ± 1.6%
Early–late apoptosis 4.4 ± 1.2% 17.6 ± 3.7%*
*P < 0.05 t-test.
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[19,20]. As suggested in many previous studies, high ex-
pression of ABCG2/BCRP on the cell membrane is a pre-
requisite for SP cells to extrude Hoechst 33342 dye and
maintain their stem cell-like characteristics [21-23]. In our
study, immunocytochemical analysis showed that BCRP
was highly expressed in the sorted SP cells, whereas non-
SP cells hardly expressed BCRP, which is consistent with
the proposed molecular mechanism mentioned above.
In addition to those surface markers, ALDH-1 (alde-
hyde dehydrogenase 1, ALDH1, ALDH1A1 or RALDH1)
has received increasing attention as a specific marker for
CSCs. ALDH-1 of the ALDH family is a cytosolic en-
zyme that catalyzes the intracellular oxidation of acetal-
dehyde to acetate, and is involved in the differentiation
and gene expression of a variety of tissues. It is also a
specific marker of normal stem cells in tissues. In recent
years, breast, lung, prostate, and pancreatic cancers have
been found to be associated with high expression of
ALDH-1 in a small number of cells with stem cell-like
characteristics [24-27]. In our study, no significant differ-
ences were observed in the expression of ALDH1 be-
tween sorted SP and non-SP cells (Figure 2), which
might due to the different origin and differentiation of
tumor cells. Further investigation is needed to treat
ALDH-1 as a cell surface stemness-related marker of
cervical cancer cells.
According to the stem cell theory of cancer, CSCs have
the potential for continuous differentiation and self-
renewal. SP cells can give rise to both SP and non-SP
cells through asymmetric division, whereas non-SP cells
can only differentiate into non-SP cells [28,29], resulting
in higher tumorigenicity of SP cells than non-SP cells. In
our experiment, however, no significant differences were
observed in the tumorigenicity between SP and non-SP
cells at doses of 1 × 105, 1 × 104, and 2 × 103 cells perTable 2 Tumorigenic potential of SP and non-SP cells in NOD
Incidence Latency (day)
Cell no Non-SP SP Non-SP
1 × 105 3/3 3/3 20.67 ± 2.89
1 × 104 2/3 2/3 30.00 ± 4.24
1 × 103 2/3 1/3 33.5 ± 9.19mouse. This result is inconsistent with asymmetric div-
ision of SP cells and the previous findings in several re-
ports [29-31]. Several recent studies have also challenged
the conventional theory of asymmetric division. In non-
small cell lung cancer, Pan et al. [32] found that SP and
non-SP cells can both further divide into SP and non-SP
cells. In another study, SP cells were obtained by re-
sorting non-SP cells isolated from C6 glioma cells and
then culturing them in a serum-containing medium for 2
weeks [33]. Furthermore, a model has been proposed in
which transformation between SP and non-SP cells can be
achieved through a shift in the localization of ABCG2/
BCRP between the cell membrane and cytoplasm [22].
Therefore, in our study, transplanted non-SP cells may have
produced SP cells, leading to no significant difference in
the tumorigenicity of the two subpopulations of cells. But
the HE staining result, however, confirmed that the differ-
entiation ability was different between SP and non-SP cells.
CSCs have the potential for self-renewal and continu-
ous differentiation. More importantly, these cells are
more resistant against radiotherapy and chemotherapy,
which is the most plausible reason for the failure of clin-
ical treatments of cancer.
In the present study, comparison of the radioresistance
and chemoresistance among HeLa, SP and non-SP cells
showed that SP cells were more resistant against radio-
therapy and chemotherapy than HeLa and non-SP cells.
As described above, high expression of ABCG2/BCRP
on the SP cell membrane is the molecular basis for
FACS of SP cells. ABCG2/BCRP pumps out not only the
Hoechst 33342 dye, but also relevant metabolites, drugs,
and toxic substances [34], thereby constituting the mo-
lecular mechanism for the drug resistance of SP cells.
One recent study from Xia P et al. [35] found some
characteristics of SP and non-SP cells have changed after
ionizing radiation. Protein levels of Bcl-2 and Bcl-xl were
decreased, while Bax expression was increased in non-SP
cells following radiation exposure. In addition, increased
activation of caspase-3 and caspase-9 were detected after
radiation exposure in non-SP cells.
In our research, the apoptosis was 2 ~ 4 times higher
in non-SP than SP cells without radiation. This is not
the direct cause of less proliferation after chemotherapy
treatment and radiation in non-SP cells, however. In the
research of Xia P et al. [35] the apoptosis rate of non-SP
cells exposed to 8 Gy radiation was 22.9% ± 0.43%,/SCID mice
Volume (cm3)
SP Non-SP SP
20.00 ± 3.61 5.22 ± 2.12 4.38 ± 1.14
23.00 ± 4.24 3.32 ± 3.50 3.63 ± 3.60
37 1.18 ± 0.72 1.37
Figure 5 Tumor formation in NOD/SCID mice and H&E staining result. (A) After inoculated with 1 × 105 (left), 1 × 104 (middle)and 2 × 103
(right) SP or non-SP cells to NOD/SCID mice, it seemed no statistically significant differences in tumorigenicity, i.e. incidence, latency and growth
rate between SP and non-SP cells. (B) Representative H&E stained photomicrographs of SP and non-SP tumors. The tumor resulting from non-SP
cell was similar to cervical adenocarcinoma, and it contained duct lumen. As for tumor induced by SP cells, tissue lost their typical characteristics
of adenocarcinoma with more obvious cell atypia and fewer duct lumen.
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posure. Some pathway may be involved in the decreasing
proliferation, increasing apoptosis and mitochondria
damage after chemotherapy and radiation in non-SP, but
not in SP cells.
In further studies of ABCG2/BCRP, an increasing
number of researchers have attempted to identify the
pathways involved in BCRP-mediated radioresistance
and chemoresistance. At present, it is widely believed
that the expression of ABCG2/BCRP on the cell surface
is positively correlated with activation of the PI3K/Akt
pathway. Liang [36] and Zhang [37] have shown that the
PI3K/Akt signaling pathway affects tumor radioresis-
tance by anti-apoptosis and activation of DNA repair
mechanisms. Moreover, in a study of malignant glioma,
Keishi [38] found that the PI3K/Akt signaling pathway
affects the radioresistance of tumor cells by mediating
the autophagy process.So far, it still remains far from clear for the exact
mechanisms of the radioresistance and chemoresistance
of SP cells and further investigations are needed.
Conclusion
In summary, a small number of SP cells were sorted from
the HeLa cervical cancer cell line, which showed strong
capacities for proliferation, anti-apoptosis, and certain de-
grees of radioresistance and chemoresistance. These SP
cells likely include stem-like tumor cells. Further study of
the sorted SP cells from HeLa cells may provide new in-
sights into the treatment of cervical cancer.
Materials and methods
Cell culture
The human cervical cancer cell line HeLa was purchased
from the American Type Culture Collection and main-
tained in the laboratory of the Department of Gynecology
Figure 6 Chemotherapy sensitivity assays of SP and non-SP cells. Growth inhibition effect of TSA on sorted SP, non-SP cells, and unsorted
HeLa cells. After 72 h of TSA treatment at various concentrations, unsorted HeLa cells and non-SP cells showed substantially suppressed growth
in a dose-dependent manner, whereas SP cells were unaffected. Data are presented as the means of three separate experiments, each performed
in triplicate. *P < 0.01, t-test.
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China). HeLa cells were maintained as adherent mono-
layer cultures in high-glucose Dulbecco Modified Eagle's
Medium (DMEM, HyClone, USA) supplemented with
10% fetal bovine serum (FBS, HyClone, USA) andFigure 7 Radiation sensitivity assays of SP, non-SP and Hela cells. SP,
significant difference were detected between SP and non-SP cells and betwe
experiments, each performed in triplicate. *P < 0.01, t-test.incubated at 37°C with 5% CO2. The medium was re-
placed every 2–3 days. At 80–90% confluency, the cells
were washed twice with PBS, and then digested with
0.25% trypsin (Sigma Aldrich, USA) and 0.02% EDTA
(Amresco, USA) (v/v, 1:3).non-SP and Hela Cells irradiated at various doses. After 7-day incubation,
en SP and Hela cells. Data are presented as the means of three separate
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HeLa cells in the logarithmic growth phase were trypsi-
nized, washed twice with PBS, and counted. Then, the
HeLa cells were resuspended in DMEM with 2% FBS
(5 × 106 cells/mL) and divided into two groups. Group 1
was incubated with the DNA binding dye Hoechst
33342 (Sigma Aldrich, USA) at a final concentration of 5
ug/mL for 90 min at 37°C with gentle agitation every
15 min. Group 2 was pretreated with 50 μg/mL verap-
amil (Sigma Aldrich, USA) for 15 min at 37°C, and then
incubated with Hoechst 33342 (final concentration:
5 μg/mL) for 90 min at 37°C with gentle agitation every
15 min. The incubation process was carried out in the
dark. The cells were then washed twice with ice-cold
PBS and resuspended in PBS containing 2% FBS and
10 mM HEPES. The cell suspension was stored at 4°C
while protected from light before FACS. Cell suspen-
sions were freshly prepared for cell sorting and stained
with PI (Sigma Aldrich, USA) at a final concentration of
2 μg/mL. Cell sorting was performed using a FACS
DIVA fluorescence-activated cell sorter (BD Biosciences,
USA). SP and non-SP cells were collected separately in
sterile 25-cm2 flasks and cultured in DMEM containing
10% FBS at 37°C with 5% CO2. Cell morphology was ex-
amined under an inverted microscope every 6 h.
Immunocytochemistry
To determine whether there were expression differences
of stem-like cell biomarkers between SP and non-SP
cells, freshly sorted SP and non-SP cells were cultured in
chamber slides under normal culture conditions over-
night. The cells were then fixed with 4% paraformalde-
hyde for 30 min at room temperature, treated with 2%
H2O2 for 30 min followed by 0.3% Triton X-100 for
30 min, and then stained with the following antibodies:
anti-Oct3/4 (mouse monoclonal, 1:400; ZSGB-BIO,
China), anti-CD133 (rabbit polyclonal, 1:1200; BioSS,
China), anti-BCRP (mouse monoclonal, 1:800; Abcam,
UK), and anti-ALDH (rabbit polyclonal, 1:1100; BioSS,
China). The negative control omitted the primary anti-
body. Cells were incubated in a humidified box at 4°C
overnight, and then the secondary antibody was added
to the cells, followed by incubation at room temperature
for 30 min. After the reaction with DAB, the cells were
smeared onto slides, examined by microscopy and
photographed with a digital camera connected to the
microscope.
Cell cycle and apoptosis analyses
Cell cycle and apoptosis analyses were both performed
after 24 hours of sorting.
The cell cycle was examined using a CycleTEST™
PLUS DNA Reagent Kit (BD Biosciences, USA) follow-
ing the manufacturer’s instructions.Cell apoptosis was examined using an Annexin V-FITC
Apoptosis Detection Kit (BSCs) following the manufac-
turer’s instructions. Briefly, the cells were counted and 5 ×
105~1 × 106 cells of each group were centrifuged at 179 g
(4°C) for 10 min. After the supernatant was removed, cold
PBS was added to the cell pellet, followed by gentle vor-
texing to resuspend the cells. Then, the cells were washed
twice, resuspended in 200 μL binding buffer containing
10 μL annexin V-FITC, and gently mixed and incubated
at room temperature for 15 min while protected from
light. Finally, 300 μL binding buffer and 50 μL PI were
added to the cell suspension, followed by flow cytometric
analysis. Each sample was prepared in triplicate.In vivo xenografting in immunodeficient mice
NOD/SCID mice were purchased from the Animal Insti-
tute of the Chinese Academy of Medical Science (CAMS)
and Peking Union Medical College (PUMC) (Certificate
No. SCXK(jing)2009-0004), and maintained in microisola-
tor cages. All experiments were approved by the Animal
Care Committee of CAMS and PUMC. Freshly sorted SP
and non-SP cells in 200 μl Matrigel (BD Biosciences,
USA) diluted in PBS at a 1:1 ratio were injected subcuta-
neously into the left axillary fossa of female NOD/SCID
mice (4–6 weeks-old). Groups of mice were inoculated
with SP or non-SP cells at 1 × 105, 1 × 104 and 2 × 103
cells, respectively. Tumor appearance was inspected
weekly by visual observation and palpation. Mice were
sacrificed after 8 weeks and the tumors were harvested,
measured, and photographed. Tumor volumes were mea-
sured using a digital caliper and approximated according
to the formula V = 1 / 2ab2, where a and b are the long
and short diameters of the tumor, respectively [30]. Tu-
mors were fixed in 10% buffered formalin, embedded in
paraffin, and then sections were prepared for H&E
staining.Chemoresistance analysis
The sensitivities to chemotherapeutic reagents of HeLa,
SP, and non-SP cells were assessed using an MTS assay.
Briefly, 2 × 103 cells per well were seeded on 96-well
plates in 200 μl per well of appropriate growth medium.
After 24 hours, the cells were treated with TSA at vari-
ous concentrations (0.01, 0.05, 0.2, and 1 μmol/L). Be-
cause TSA is unstable in water and degrades easily, fresh
TSA was added every 24 h. After 72 h, the cells were
washed and fresh medium was added, followed by 20 μl
Cell Titer 96®AQueous One Solution (Promega, USA) to
each well. The cells were then incubated for 1~4 h at
37°C in a humidified atmosphere with 5% CO2. The ab-
sorbance at 490 nm was measured using a plate reader.
The blank control was prepared using untreated cells.
Each treatment was performed in triplicate.
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Sorted SP and non-SP cells as well as unsorted HeLa
cells were transferred to 25-cm2 flasks and incubated in
DMEM with 10% FBS at 37°C with 5% CO2 for 24 h.
The flasks were placed on a linear accelerator Clinac
600C/D (VARIAN, USA) with a fixed source skin dis-
tance at 100 cm and X-ray irradiation at 4 Gy/min. The
flasks were covered with a 1.5 cm-thick wax film during
X-ray irradiation. Three treatments were carried out at
1, 2, and 4 Gy, respectively. The controls were not ex-
posed to X-rays and were cultured under normal condi-
tions. After X-ray irradiation, cells were digested with
trypsin and resuspended in DMEM with 10% FBS for
cell counting. The cells were transferred to 96-well
plates (2000 cells/well) and cultured for 7 days. The
medium was replaced every other day. To generate a ra-
diation survival curve, the SF of cells at each radiation
dose was normalized to that of the sham-irradiated con-
trol (ibid).
Statistical analysis
We run the SPSS 19.0 statistical software to process the
data and applied the t-test and Fisher's exact test to
evaluate if significant differences exist between groups
according to the criterion (P < 0.05).
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